The human body is an extremely complex molecular machine, the details of which can be followed through certain substances; so-called biomarkers. Unfortunately, it is not yet possible to monitor biomarkers live in patients when these are present in minuscule concentrations. Researchers at Eindhoven University of Technology have now developed a new technique that can become the plain and simple solution for the live and super-sensitive monitoring of biomarkers.
They report on it in Nature Communications.
Substances that are essential for the body, such as proteins and hormones, are present in the blood in pico- or nanomolar concentrations. These are concentrations comparable to 1 sugar grain dissolved in an Olympic-sized swimming pool – extremely low, and difficult to measure. In the Molecular Biosensing for Medical Diagnostics group at Eindhoven University of Technology, under the guidance of Professor Menno Prins, a sensing technology has been developed that enables the super-sensitive measurement of biomarker concentrations over time.
The technique is based on the fact that tiny particles in liquid are continuously in Brownian motion because water molecules collide with them. The researchers bound the particles through a nanostrand to a glass plate, causing the particles to wiggle back and forth. The biomarker to be measured binds temporarily to specific adhesive molecules that are fixed to both the particles and the plate. When a biomarker molecule attaches itself to both a wiggling particle and to the plate, the particle suddenly becomes attached, which greatly reduces its mobility – until the biomarker is released again.
The mobility of the particles, which are coupled to the transparent glass, could be easily observed by the researchers with light. They have given their technology the name BPM: Biomarker monitoring based on sensing of Particle Mobility. Every time a wiggling particle suddenly moves less, and then more, one biomarker molecule has been observed. The number of these events per minute reveals the concentration of the biomarker in the liquid with a high degree of sensitivity.
The principle is explained in this animation video: https:/
The beauty of the BPM sensor technology is that it has digital precision, and that both increases and decreases in biomarker concentration over time can be monitored. The technique has now been demonstrated for the monitoring of protein and DNA. The technology is widely applicable, because suitable adhesion molecules are available for almost all biomarkers.
This flexibility, combined with the sensitivity and the expected miniaturization of the technology, means that Prins and his fellow researchers have high expectations of the future for their technology. “We anticipate that a completely new class of sensors for the monitoring of biomarkers will emerge from this,” says the professor, so he is creating a start-up that will develop practical sensors and applications. One of the possibilities is to connect a sensor to a catheter with which patients in the operating room or in the intensive care unit can be accurately monitored. In addition to medical applications, Prins also thinks there are possibilities for monitoring biomolecules in industrial processes and water purification.
The Latest on: Monitoring of biomarkers
via Google News
The Latest on: Monitoring of biomarkers
- Vocal Biomarker Market Assessment and Key Insights Analyzed till 2027on September 6, 2019 at 6:54 pm
Remote health monitoring potential of vocal biomarkers is also gaining high interest among researchers worldwide, For example, Beyond Verbal and Mayo Clinic have collaborated for discovering vocal ...
- Creative Biolabs Is a Leading Service Provider of In Vitro Diagnosticson September 6, 2019 at 3:55 pm
Targeting at the Autoimmune Diseases Biomarkers Malfunctions in the immune system of human body may result in the loss of competence of discriminating the self and non-self cells, and thus causing the ...
- Label-Free Array Systems Market: Preeminent Players Look to Invest in Surface Plasmon Resonance Technologyon September 6, 2019 at 9:18 am
The multiplexed approach to protein monitoring has been instrumental for fundamental biomedical research and propelled the strategies for discovery of new disease biomarkers. The technological ...
- Urinary estrogens as a non-invasive biomarker of viable pregnancy in the giant panda (Ailuropoda melanoleuca)on September 4, 2019 at 2:13 am
Non-invasive longitudinal monitoring of estrogen concentrations therefore has ... urinary estrogens corrected for USpG provides noteworthy potential as a non-invasive biomarker of ongoing pregnancy in ...
- Liquid Biopsies Intensify Surveillance of ctDNAon September 3, 2019 at 4:37 am
Some of the most advanced tools for detecting circulating biomarkers were highlighted at a recent industry ... from risk assessment and early detection through monitoring of therapy effectiveness and ...
- Alnylam Presents New Clinical Research Findings at the Second European Meeting of ATTR Amyloidosis for Doctors and Patientson September 3, 2019 at 4:30 am
“These new clinical research findings provide important insights on a potential biomarker for monitoring polyneuropathy and response to treatment, and highlight human genetic data showing no evidence ...
- A protocol integrating remote patient monitoring patient reported outcomes and cardiovascular biomarkerson September 3, 2019 at 2:07 am
Ischemic heart disease (IHD) is the leading cause of death in the United States in men and women across all ethnicities. 1 Although lifestyle risk factors associated with IHD such as smoking, physical ...
- Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depressionon August 31, 2019 at 2:11 pm
About sphingotec SphingoTec GmbH ("sphingotec"; Hennigsdorf by Berlin, Germany) develops and markets innovative in vitro diagnostic IVD tests for novel and proprietary biomarkers for the diagnosis, ...
- Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depression. sphingotec launches first IVD test for DPP3 on Nexus IB10 Point-of-Care platformon August 31, 2019 at 7:00 am
The DPP3 biomarker indicates angiotensin II and enkephalin ... and proprietarybiomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure ...
via Bing News